PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24269216-0	2014	Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.	(6-((4'-(3,4-dihydroxybutoxy)-2,2',6'-trimethyl(1,1'-biphenyl)-3-yl)methoxy)-3H-spiro(1-benzofuran-2,1'-cyclopropan)-3-yl)acetic acid	20-29	free fatty acid receptor 1	Mus musculus	6-11	
24269216-0	2014	Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.	Glucose	39-46	free fatty acid receptor 1	Mus musculus	6-11	
24269216-0	2014	Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.	Sitagliptin Phosphate	98-109	free fatty acid receptor 1	Mus musculus	6-11	
24269216-4	2014	MAIN METHODS: We evaluated acute glucose metabolism on insulin and GLP-1 secretion using an oral glucose tolerance test (OGTT) as well as assessed the chronic glucose metabolism in diabetic ob/ob mice following the repeated administration of AS2575959.	Glucose	33-40	glucagon	Mus musculus	67-72	
24269216-6	2014	Further, we observed a synergistic effect of AS2575959 and DPP-IV inhibitor on insulin secretion and plasma GLP-1 level.	(6-((4'-(3,4-dihydroxybutoxy)-2,2',6'-trimethyl(1,1'-biphenyl)-3-yl)methoxy)-3H-spiro(1-benzofuran-2,1'-cyclopropan)-3-yl)acetic acid	45-54	glucagon	Mus musculus	108-113